

We claim:

1. ✓ A method for the treatment of asthma in a patient, comprising administering to the patient a composition comprising delipidated and deglycolipidated *M. vaccae* cells, wherein the delipidated and deglycolipidated *M. vaccae* cells comprise less than 10% by weight of lipids.
2. The method of claim 1, wherein the composition is administered intranasally.
3. The method of claim 1, wherein the composition is administered subcutaneously.
4. The method of claim 1, wherein the composition additionally comprises an adjuvant.
5. ✓ A method for the treatment of asthma in a patient, comprising administering to the patient a composition comprising delipidated and deglycolipidated *M. vaccae* cells, wherein the delipidated and deglycolipidated *M. vaccae* cells comprise more than 33% by weight of amino acids.
6. The method of claim 5, wherein the composition is administered intranasally.
7. The method of claim 5, wherein the composition is administered subcutaneously.
8. The method of claim 5, wherein the composition additionally comprises an adjuvant.

2023.10.10 15:49:15